Pasar al contenido principal

PAPEL DE LA S-ADENOSILMETIONINA (SAME) EN LA PATOGENESIS Y TRATAMIENTO DE LA ENFERMEDAD DEL HIGADO GRASO NO-ALCOHOLICA

SAF2014-52097-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2014
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

  • Fernández Tussy, Pablo
  • Rodríguez Agudo, Rubén
  • Fernández Ramos, David
  • Barbier Torres, Lucía
  • Zubiete Franco, Imanol
  • Davalillo, Sergio López de
  • Herráez, Elisa
  • Goikoetxea Usandizaga, Naroa
  • Lachiondo Ortega, Sofía
  • Simón, Jorge
  • Lopitz Otsoa, Fernando
  • Gutiérrez de Juan, Virginia
  • McCain, Misti V.
  • Perugorría, María J.
  • Mabe, Jon
  • Navasa Mayo, Nicolás
  • Rodrigues, Cecilia M. P.
  • Fabregat, Isabel
  • Boix, Loreto
  • Sapena, Víctor
  • Anguita, Juan
  • Lu, Shelly C.
  • Mato, José M.
  • Banales, Jesus M.
  • Villa, Erica
  • Reeves, Helen L.
  • Bruix, Jordi
  • Reig, María
  • Marín, José J. G.
  • Delgado, Teresa C.
  • Martínez Chantar, María L.
[EN]Dysregulation of miRNAs is a hallmark of cancer, modulating oncogenes, tumor suppressors, and drug responsiveness. The multi-kinase inhibitor sorafenib is one of the first-line drugs for advanced hepatocellular carcinoma (HCC), although the outcome for treated patients is heterogeneous. The identification of predictive biomarkers and targets of sorafenib efficacy are sorely needed. Thus, selected top upregulated miRNAs from the C19MC cluster were analyzed in different hepatoma cell lines compared to immortalized liver human cells, THLE-2 as control. MiR-518d-5p showed the most consistent upregulation among them. Thus, miR-518d-5p was measured in liver tumor/non-tumor samples of two distinct cohorts of HCC patients (n = 16 and n = 20, respectively). Circulating miR-518d-5p was measured in an independent cohort of HCC patients receiving sorafenib treatment (n = 100), where miR-518d-5p was analyzed in relation to treatment duration and patient’s overall survival. In vitro and in vivo studies were performed in human hepatoma BCLC3 and Huh7 cells to analyze the effect of miR-518d-5p inhibition/overexpression during the response to sorafenib. Compared with healthy individuals, miR-518d-5p levels were higher in hepatic and serum samples from HCC patients (n = 16) and in an additional cohort of tumor/non-tumor paired samples (n = 20). MiR-518d-5p, through the inhibition of c-Jun and its mitochondrial target PUMA, desensitized human hepatoma cells and mouse xenograft to sorafenib-induced apoptosis. Finally, serum miR-518d-5p was assessed in 100 patients with HCC of different etiologies and BCLC-stage treated with sorafenib. In BCLC-C patients, higher serum miR-518d-5p at diagnosis was associated with shorter sorafenib treatment duration and survival. Hence, hepatic miR-518d-5p modulates sorafenib resistance in HCC through inhibition of c-Jun/PUMA-induced apoptosis. Circulating miR-518d-5p emerges as a potential lack of response biomarker to sorafenib in BCLC-C HCC patients., SI, This work was supported by grants from NIH (US Department of Health and Human services) R01CA172086 (to S.C.L., J.M.M. and M.L.M.-C.) and P01CA233452 (to S.C.L.), Gobierno Vasco-Departamento de Salud 2013111114 (to M.L.M.-C), MINECO: SAF2017-87301-R, SAF2014-52097-R, RTI2018-096759-A-100, SAF2016-75197-R and SAF2015-64149-R, integrated in the Plan Estatal de Investigación Cientifica y Técnica e Innovación 2017-2020 cofounded by FEDER funds/Development Fund—a way to build Europe (to M.L.M.-C., J.M.M., T.C.D., J.J.G.M., and I.F., respectively), Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain: PI16/00598 and PI19/00819 (to J.J.G.M.), PI15/01132 and PI18/01075 (to J.M.B.), PI14/00399 and PI17/00022 (to M.J.P.), PI18/0358 (to M.R.), BIOEF (Basque Foundation for Innovation and Health Research): EITB Maratoia BIO15/CA/014 and BIO15/CA/016/BD (to M.L.M.-C and J.M.B., respectively); Mitotherapeutix (to M.L.M.-C), Consejería de Educación, Junta de Castilla y León: SA063P17 (J.J.G.M.), Asociación Española Contra el Cáncer (T.C. D, P.F.-T., and M.L.M-C), Basque Government Postdoctoral Program (P.F.-T.), Daniel Alagille award from EASL (to T.C.D.), Asociación Española contra el Cáncer, Canceres raros (M.L.M.-C., J.M.B., and J.J.G.M.), La Caixa Foundation (to M.L.M.-C. and J.M.B.), Ayudas Fundación BBVA a equipos de Investigación Científica 2018 (to M.L.M.-C.), Fondo Europeo de Desarrollo Regional’ (FEDER) (to J.M.B.); CIBERehd, Spain (to J.M.B.); IKERBASQUE, Basque foundation for Science, Spain (to J.M.B.), Department of Health of the Basque Country (2017111010) (to J.M.B.), Euskadi RIS3 (2019222054, 2020333010) (to J.M.B.); Department of Industry of the Basque Country (J.M.B.: Elkartek: KK-2020/00008) (to J.M.B.), Ayudas para apoyar grupos de investigación del sistema Universitario Vasco IT971, Instituto de Salud Carlos III PI18/00768 (J.B.), AECC PI044031 (J.B.), Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement 2014 SGR 605 (J.B.), WCR (AICR) 16-0026 (J.B.), Programma di ricerca Regione-Università 2007–2009 and 2011–2012, Regione Emilia- Romagna (E.V.).
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Reseña (Review)

The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury

  • Barbier-Torres, Lucía
  • Iruzubieta, Paula
  • Fernández-Ramos, David
  • Delgado, Teresa C.
  • Taibo, Daniel
  • Gutiérrez de Juan, Virginia
  • Varela‐Rey, Marta
  • Azkargorta, Mikel
  • Navasa Mayo, Nicolás
  • Fernández-Tussy, Pablo
  • Zubiete-Franco, Imanol
  • Simón, Jorge
  • Lopitz-Otsoa, Fernando
  • Lachiondo-Ortega, Sofia
  • Crespo, Javier
  • Masson, Steven
  • McCain, Misti Vanette
  • Villa, Erica
  • Reeves, Helen L.
  • Elortza, Félix
  • Lucena, María Isabel
  • Hernández-Álvarez, Maria Isabel
  • Zorzano, Antonio
  • Andrade, Raúl J.
  • Lu, Shelly C.
  • Mato, José M.
  • Anguita, Juan
  • Rincón, Mercedes
  • Martínez‐Chantar, María Luz
[EN]Acetaminophen (APAP) is the active component of many medications used to treat pain and fever worldwide. Its overuse provokes liver injury and it is the second most common cause of liver failure. Mitochondrial dysfunction contributes to APAP-induced liver injury but the mechanism by which APAP causes hepatocyte toxicity is not completely understood. Therefore, we lack efficient therapeutic strategies to treat this pathology. Here we show that APAP interferes with the formation of mitochondrial respiratory supercomplexes via the mitochondrial negative regulator MCJ, and leads to decreased production of ATP and increased generation of ROS. In vivo treatment with an inhibitor of MCJ expression protects liver from acetaminophen-induced liver injury at a time when N-acetylcysteine, the standard therapy, has no efficacy. We also show elevated levels of MCJ in the liver of patients with acetaminophen overdose. We suggest that MCJ may represent a therapeutic target to prevent and rescue liver injury caused by acetaminophen., SI
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  • Zabala-Letona, Amaia
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Martín Martín, Natalia
  • Fernández Ruiz, Sonia
  • Sutherland, James D.|||0000-0003-3229-793X
  • Clasquin, Michelle
  • Tomás Cortázar, Julen
  • Jiménez, José
  • Torres Ramírez, Inés Ma. de
  • Quang, Phong
  • Ximénez-Embún, Pilar|||0000-0002-2582-9443
  • Bago, Ruzica
  • Ugalde Olano, Aitziber
  • Loizaga Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Torrano, Verónica
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Cendon, Ylenia
  • Castro, Elena|||0000-0002-3691-6454
  • Murray, Stuart
  • Revandkar, Ajinkya
  • Alimonti, Andrea
  • Zhang, Yinan
  • Barnett, Amelia
  • Lein, Gina
  • Pirman, David
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Arreal, Leire
  • Prudkin, Ludmila
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel-Jimenez, Lorea
  • Zúñiga-García, Patricia
  • Fernández Domínguez, Itziar
  • Piva, Marco
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Sánchez Mosquera, Pilar
  • Castillo Martín, Mireia
  • Serra, Violeta|||0000-0001-6620-1065
  • Beraza, Naiara
  • Gentilella, Antonio|||0000-0002-6830-2086
  • Thomas, George|||0000-0002-1236-1714
  • Azkargorta, Mikel
  • Elortza, Felix|||0000-0001-8839-5438
  • Farràs, Rosa
  • Olmos, David
  • Efeyan, Alejo
  • Anguita, Juan
  • Muñoz, Javier|||0000-0003-3288-3496
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Barrio, Rosa|||0000-0002-9663-0669
  • Macarulla Mercadé, Teresa|||0000-0002-5856-4082
  • Mato, José M.
  • Martínez Chantar, Maria L.
  • Cordon Cardo, Carlos
  • Aransay, Ana M.|||0000-0002-8271-612X
  • Marks, Kevin
  • Baselga Torres, Josep
  • Tabernero, Josep|||0000-0002-2495-8139
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Manning, Brendan D.
  • Marjon, Katya
  • Carracedo, Arkaitz|||0000-0001-5957-1260
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation,. Here we show that mTORC1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. Through the use of integrative metabolomics in a mouse model and human biopsies of prostate cancer, we identified alterations in tumours impacting on the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation was validated in murine and human cancer specimens. AMD1 was upregulated in prostate cancer specimens with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus exhibited a predominant decrease in AMD1 immunoreactivity that was associated to a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.